Tonsil Beta Amyloid Detection for Alzheimer's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease are invasive, expensive, and not suitable for early screening in large populations, as they require brain imaging or cerebrospinal fluid examination, lacking a reliable method using tonsil tissue for predicting disease onset.
Innovation Solution
Measuring the expression level or plaque accumulation of beta amyloid and Staphylococcus aureus in tonsillar samples to determine the risk of developing Alzheimer's disease, using techniques such as Western blotting, ELISA, or immunofluorescence staining, and using tonsillectomy as a potential preventive measure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If brain imaging or cerebrospinal fluid examination is used for Alzheimer's disease diagnosis, then diagnostic accuracy is improved, but invasiveness and cost increase
Solution Approach 1:
The patent extracts the diagnostic target (beta amyloid protein) from the brain tissue to the tonsil tissue, which is accessible through simple biopsy. This allows detection of Alzheimer's disease markers without invasive brain imaging or cerebrospinal fluid extraction, resolving the contradiction between diagnostic accuracy and ease of operation
Solution Approach 2:
The patent uses tonsil tissue as an intermediary sample that reflects brain pathology. Instead of directly examining brain tissue, the tonsil serves as a surrogate that contains beta amyloid protein levels correlated with brain amyloid accumulation, enabling non-invasive diagnosis while maintaining diagnostic accuracy
2Measurement precision
If brain imaging or cerebrospinal fluid examination is used for Alzheimer's disease diagnosis, then diagnostic accuracy is improved, but cost increases
Solution Approach 1:
The patent employs simple, inexpensive biopsy techniques and standard laboratory methods (Western blotting, ELISA, immunohistochemistry) to detect beta amyloid in tonsil tissue. These disposable, routine procedures are far cheaper than advanced brain imaging equipment or specialized cerebrospinal fluid analysis, reducing cost while maintaining diagnostic accuracy
3Ease of operation
If tonsil tissue is used for Alzheimer's disease prediction, then ease of sampling is improved, but measurement precision is insufficient
Solution Approach 1:
The patent replaces mechanical brain imaging systems with biochemical detection methods (Western blotting, ELISA, immunohistochemistry) that can accurately quantify beta amyloid protein in tonsil tissue. This substitution maintains ease of sampling while achieving reliable measurement precision through sensitive biochemical assays
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for early diagnosis and prevention of Alzheimer's disease by identifying beta amyloid and Staphylococcus aureus in tonsil samples, providing a non-invasive and cost-effective approach for screening and potentially delaying or preventing disease progression.
Implementation Method 1
measuring an expression level or plaque accumulation level of beta amyloid in a tonsillar sample obtained from a subject
Data Source
AI summary
The present disclosure relates to the detection of beta amyloid protein as an Alzheimer's disease-causing factor in the palatine tonsil and a use thereof and, more specifically, to the diagnosis of Alzheimer's disease by identifying the expression of beta amyloid and/or Staphylococcus aureus in a tonsillar sample. The present disclosure can diagnose Alzheimer's disease through the expression of beta amyloid and/or Staphylococcus aureus in a palatine tonsil tissue and, furthermore, can be very advantageously used for revealing the pathogenesis of Alzheimer's disease and for treating Alzheimer's disease.